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Immunological quantification of advanced glycosylation end-products
in the serum of patients on hemodialysis or CAPD. We have developed
an immunological procedure for measuring advanced glycosylation
end-products (AGEs) in serum. Using this method, we measured AGEs
in healthy volunteers, patients with diabetes, renal failure without
treatment and in patients with renal failure, treated with hemodialysis
(HD) or continuous ambulatory peritoneal dialysis (CAPD). We found
that AGEs were moderately elevated in diabetics without renal failure
and highly elevated in CAPD and HD patients irrespective of their
glycemic status. AGE levels correlated significantly with creatinine
levels but not with levels of glucose or patient age or sex. AGE levels
were reduced significantly post-hemodialysis. Preliminary experiments
have shown that circulating AGEs have a molecular weight of approx-
imately 1.5 to 2.0 kDa. More studies are needed to establish if AGE
measurements in serum are prognostic indicators of the complications
of either diabetes or renal failure.
Reducing sugars such as glucose react non-enzymatically
with the free amino groups of proteins to form stable Amadori
products through Schiff base adducts. Once formed, Amadori
products undergo further modifications to produce a diverse
group of protein-bound moieties with cross linking properties
called advanced glycosylation end-products (AGEs) [1—3].
AGEs accumulate naturally over the lifespan or under condi-
tions of high sugar concentration such as in diabetes mellitus.
Several experimental studies suggest that AGE accumulation in
the body may cause structural and functional changes of
proteins during aging and may play a role in the long-term
complications of diabetes mellitus [4—6].
Patients with end-stage renal disease who are undergoing
peritoneal dialysis include a large proportion of elderly and
diabetics. We speculated that this group may be in an increased
risk of accumulating AGEs because of the high concentration of
glucose used as osmotic agent in the peritoneal dialysis fluid.
Until now, no studies have been reported on the levels of AGEs
in the serum of patients undergoing peritoneal dialysis. We
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examined serum AGE levels in various patient groups including
peritoneal dialysis and hemodialysis patients, using an immu-
nological procedure that we developed. Three independent
reports have recently confirmed that it is possible to raise
antibodies reacting with diverse AGEs, including those pro-
duced by reacting glucose with amino acids [7—9]. These reports
speculate that all AGEs share a common haptenic antigenic
determinant which is very useful for monitoring AGE levels in
tissues and serum.
Methods
Reagents
Bovine pancreatic ribonuclease (RNase), bovine serum albu-
min (BSA) and all sugars used were from Sigma Chemical Co.
(St. Louis, Missouri, USA). AGE-RNase (the immunogen) was
prepared by mixing 10 ml of phosphate buffer (0.2 mollliter, pH
7.40, containing 0.5 mmol EDTA) 250 mg RNase and 1.80 g
glucose, dissolving and filtering through a 0.2 m filter and
incubating for three months at 37°C (air-oven) [9]. One prepa-
ration without glucose was incubated under the same conditions
as a control. The same procedure was also used to prepare an
AGE-BSA solution which was used as a coating antigen in the
assay, as described below. The stock AGE-BSA solution con-
tained 50mg of BSA/mI. Mter incubation, the unbound material
was removed by extensive dialysis against phosphate-buffered
saline.
Immunization
While female New Zealand rabbits were immunized with the
AGE-RNase immunogen, which was emulsified with an equal
volume of complete Fruend's adjuvant (Sigma). About 50 d of
immunogen were injected subcutaneously every two to three
weeks at two different sites. Just prior to each injection, blood
was drawn for antibody testing. A total of eight injections were
given, and all booster injections were performed with the
immunogen in incomplete adjuvant. High titers of antibodies
developed after 10 to 12 weeks. The development of the AGE
antibodies was monitored with a solid-phase assay described
under "Procedures." The rabbit antiserum was used without
further purification.
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Fig. 1. Competitive immunoassay for AGE
using the immobilized antigen approach.
Abbreviations are: ALP, alkaline
phosphatase; FSAP, 5-fluorosalicyl phosphate;
FSA, 5-fluorosalicylate.
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Fig. 2. Typical calibration curve for the AGE assay (EU. The fluores-
cence of the zero standard was 67,409 arbitrary units and was defined as
Bo. The fluorescence of all other standards was defined as B. In the
same plot we present the (BIB0) x 100 values of a serum sample that
was analyzed undiluted or diluted 2-, 4- or 8-fold (•).
Instrumentation
For measuring liquid-phase Tb3 fluorescence in white mi-
crotiter wells, the CyberFluor 615TM Immunoanalyzer, a time-
resolved fluorometer, was used as previously described [10,
111.
Table 1. Within-run precision of the AGE assay
AGE, U/mi
C.V. % (N = 12)Mean SD
5.1 0.56 11.4
11.3 0.90 8.0
12.2 1.3 11.3
18.5 2.0 10.6
37.3 3.0 8.1
55.7 4.3 7.8
Abbreviations are: SD, one standard deviation; N, number of repli-
cates.
Solutions
The enzyme substrate buffer was a 0.1 mollliter Tris solution,
pH 9.1, containing 0.1 mol NaCl and 1 mmol MgC12 per liter.
The stock 5-fluorosalicyl phosphate (FSAP) substrate solution
was a 10—2 mollliter solution in 0.1 mollliter NaOH. Fresh
FSAP substrate working solutions were prepared just before
use by 10-fold dilution of the stock in the enzyme substrate
buffer. The developing solution was a 1 mollliter Tris base
solution containing 0.4 mol NaOH, 3 mmol EDTA and 2 mmol
TbC13 6H20 per liter (no pH adjustment). The wash solution
was a 5 mmollliter Tris buffer, pH 7.80, containing 0.5 g Tween
20 and 150 mmol NaC1 per liter. The coating solution was a 0.1
moliliter carbonate buffer, pH 9.50. The standard diluent was a
50 mmollliter Tris buffer, pH 7.80, containing 60 g of BSA and
0.5 g of NaN3 per liter. The assay buffer was a 50 mmollliter
Tris buffer, pH 7.80, containing 60 g BSA, 0.5 mol KC1 and 10
ml normal goat serum per liter. The alkaline phosphatase-
labeled goat anti-rabbit immunoglobulin, approximately 1 mg/
ml, was obtained from Jackson Immunoresearch (West Grove,
Pennsylvania, USA).
For the AGE assay, a series of six standard solutions with
concentrations of 0, 1.7, 3.4, 6.8, 27.5 and 110 U/mI was used.
1÷
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BSA-AGE
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Table 2. Recovery studies
AGE, U/mi
% Recoverya
Initially
present (A)
Added
(B)
Total measured
(C)
Recovered
(D)
10.6 14.1
33.7
63.2
29.1
45.0
70.6
18.5
34.4
60.0
131
102
95
5.9 14.1
33.7
63.2
22.3
36.5
61.8
16.4
30.6
55.9
116
91
89
8.2 14.1
33.7
63.2
28.6
46.6
56.9
20.4
38.4
48.7
144
114
77
8.1 14.1
33.7
63.2
24.0 15.9 113
37.8 29.7 88
70.0 61.9 98
Average: 105 19%
a Recovered concentration D = C — A. Recovery = (D/B) X 100
60
20
0
% of Serum, dilution factor
These standards were prepared from a stock AGE-BSA solu-
tion with total protein of 50 mg/mI, equivalent to 50,000 U/ml.
As also defined by others [9], one AGE unit is equivalent to 1 sg
of AGE-BSA.
Patient samples and statistical analysis
Sera from various groups of patients were stored at —70°C
until analysis (up to 2 months). All comparisons were deter-
mined by paired or unpaired Student's t-test as appropriate. All
P values of less than 0.05 were considered to indicate statistical
significance.
Immunoassay procedure
White, opaque 12-well microtiter strips (from Dynatech
Labs, Alexandria, Virginia, USA) were coated with the AGE-
BSA complex diluted in the coating buffer (100 dI2.5 zgIwell;
overnight incubation at room temperature). Before the assay,
the wells were washed six times with the wash solution, using
an automated washing device. In each well 100 p1 of each
standard or serum sample (all in triplicate) were added to 50 d
of the rabbit anti-AGE antiserum diluted 2,000-fold in the assay
buffer, incubated with shaking for two hours at room tempera-
ture and washed six times. One hundred p1/well of the alkaline
phosphatase-labeled goat anti-rabbit immunoglobulin was
added, diluted 5,000-fold in the assay buffer, incubated for one
hour as above and washed six times. One hundred p1/well of the
alkaline phosphatase substrate FSAP, diluted to iO mol/liter
in the enzyme substrate buffer was added, and incubated for 10
minutes at room temperature with shaking. Then, 100 p1/well of
the developing solution was added, mixed for one minute, and
the Th3-specific fluorescence measured in the time-resolved
mode as previously described [10, 11]. Data reduction was
automatic through the CyberFluor 615TM Immunoanalyzer.
To monitor antibody titers during immunization, a similar
assay procedure was used. The differences are as follows: (a)
only the zero standard was used, and (b) the antiserum was
used at various dilutions. The antibody titer was defined as the
antiserum dilution that gave 50% of the maximum fluorescence
count. For the assay, the antiserum titer was about 2,000.
Fig. 3. Dilution of three samples with high AGE concentration. Sam-
pies were run undiluted (dilution factor 100) or diluted 2-fold, 4-fold and
8-fold. Linear regression analysis gave correlation coefficients of r
0.98 in all cases.
Results
AGE formation of RNAse and BSA during the incubation
periods (90 days) was monitored by fluorometry. Fluorometric
measurements revealed fluorescence associated only with the
AGE-RNase and AGE-BSA complexes, and not with the con-
trol mixtures of BSA and RNase with glucose and without
incubation. The excitation and emission maxima of AGEs were
found to be 360 and 445 nm, respectively, which is in close
agreement with previously published data [12].
The immunological procedure that we developed was similar
to the one described by Makita et al [9], but for detection, we
used a methodology based on enzymatically amplified time
resolved fluorometry with terbium chelates, as previously de-
scribed [10, 11]. In our assay (Fig. 1) immobilized AGE
(AGE-BSA) competed with the AGE in the serum sample or
standards, for binding to a limited amount of anti-AGE rabbit
antibodies. The degree of binding of the antibody to the
solid-phase was inversely related to the amount of AGE in the
sample. Antibody binding was quantified with a goat anti-rabbit
antibody covalently linked to alkaline phosphatase (ALP). The
ALP substrate used was FSAP, which was converted to 5-flu-
orosalicylate (FSA). FSA is able to form a ternary fluorescent
complex with Th-EDTA of a long fluorescence lifetime [13].
A typical calibration curve for the AGE assay is shown in
Figure 2. This assay measured AGE up to 110 U/mi and had a
detection limit of approximately 1 U/mi. The precision of the
assay at various AGE concentrations is shown in Table 1.
Recovery experiments done by spiking patient sera with AGE-
BSA are summarized in Table 2. The possible interference of
simple sugars, that is, glucose, xylitol, dulcitol and galactose,
was tested at concentrations as high as 60 mmol/liter and of
heparin at contentrations up to 1000 U/mI. None interfered to
50
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Table 3. Serum levels of AGE in various groups of patients
Group N
Age, years
Mean SDd
Glucose
mmol/liter
Mean SD
Creatinine
j.unol/!iter
Mean sud
AGE, U/mi
Mean so' Minimum Maximum
Normal subjects 18 47 16 — — — — 7.8 2.3 3.9 11.7
Diabetics, no renal failure 24 56 14 11.0 4.0 123 45 15.0 5.5 4.6 28.4
NIDDM 15 56 13 11.0 4.3 128 49 16.2 5.2 8.8 28.4
IDDM 9 57 16 11.0 3.6 114 32 12.8 5.7 4.6 18.7
Renal failure, non-treated 9 67 17 4.3 2.0 367 225 25.4 14.3 16.0 66.2
CAPD 26 51 18 8.6 5.0 762 360 29.5 13.3 11.6 60.2
Non-diabetics 14 53 21 5.8 1.9 885 262 31.3 16.6 11.6 60.2
NIDDM 3 39 13 8.4 5.4 585 294 25.7 6.4 20.1 32.7
IDDM 9 53 16 13.0 5.5 817 277 28.2 9.0 16.1 43.5
Hemodialysis patients 21 61 14 7.0 3.6 534 330 24.0 9.6 9.7 49.0
Nondiabeticsprea
Non-diabetics-post"
6
6
57
57
19
19
5.1
4.3
0.4
0.5
951 165
394 63
38.1
16.3
7.2
5.8
30.3
9.7
49.0
26.1
NIDDM-pre 4 68 9 9.2 1.6 674 72 32.7 4.8 19.3 37.2
NIDDM-post 4 68 9 6.3 1.4 274 32 18.2 5.5 11.7 23.5
NIDDMRc 4 72 8 11.0 5.3 279 67 22.0 6.9 11.8 29.6
IDDM-pre 1 53 — 10.0 — 567 — 31.3 — — —
IDDM-post 1 53 — 10.4 — 337 — 25.3 — — —
IDDMRC 6 55 13 5.4 1.2 582 404 25.0 4.8 17.9 31.2
Abbreviations are: N, number of patients; NIDDM, non-insulin dependent diabetes mellitus; IDDM, insulin dependent diabetes mellitus; CAPD,
continuous ambulatory peritoneal dialysis.
a Sample was taken before hemodialysis
b Sample was taken after hemodialysis
C R, random samples between hemodialysis treatments
d SD, one standard deviation
any measurable degree. Three samples with high AGE concen-
tration were analyzed undiluted or diluted two-, four- or eight-
fold using a 6% BSA solution as diluent. The results are shown
in Figure 3. The near-linear relationship between AGE concen-
tration and dilution further suggested that the AGEs in serum
and AGE-BSA share a common antigenic determinant [7—9]. A
serum sample was plotted, diluted either two-, four- or eightfold
along with the standard curve (Fig. 2). For this experiment, the
AGE concentration in the undiluted sample was calculated from
the standard curve and the fluorescence of the dilutions plotted,
expressed as (B/Bo) x 100, versus the concentration of AGE as
predicted by the dilution factor. The two curves, obtained with
AGE-BSA and diluted serum, are closely related (Fig. 2).
The results of AGE analysis in various groups of patients are
summarized in Table 3. The mean values of AGEs in normal
subjects and diabetics with normal renal function were statisti-
cally different (P < 0.001). Patients with renal failure without
diabetes and patients treated with continuous ambulatory pen-
toneal dialysis (CAPD) or hemodialysis had highly elevated
serum levels of AGE, irrespective of their glycemic status.
Comparison of various groups of patients with respect to AGE
concentration, by the Student's 1-test, revealed highly signifi-
cant differences between the following groups: normals versus
diabetics; normals versus NIDDM; normals versus IDDM;
normals versus CAPD (all patients); normals versus hemodial-
ysis (all patients); diabetics versus CAPD (all patients); and
diabetics versus hemodialysis (all patients). In all cases the P
values were <0.004. In contrast, comparison of the following
groups with respect to AGE concentration gave no statistically
significant differences: CAPD versus hemodialysis (P = 0.13);
renal failure patients (non-treated) versus CAPD (P = 0.56);
renal failure patients (non-treated) versus hemodialysis (P =
0.72); CAPD, non-diabetics versus CAPD, NIDDM (P = 0.59);
CAPD, non-diabetics versus CAPD, IDDM (P = 0.62).
The results of whether AGE concentration was associated
with serum glucose or creatinine levels, sex or age are summa-
rized in Figure 4. No correlation or association existed between
AGE levels and glucose, sex or age. However, there was a
strong correlation between AGE levels and creatinine in both
the CAPD and hemodialysis patient groups. The variation of
AGE levels during hemodialysis was also examined. For these
studies, predialysis and postdialysis AGE and creatinine levels
were compared in three groups of patients: non-diabetics,
NIDDM and IDDM (Fig. 5). In all cases there was a highly
significant drop in AGE levels after hemodialysis, which sug-
gests that the AGEs are relatively effectively cleared.
Nine patients were studied to determine if the AGE accumu-
lation in renal failure patients was the result of the hemodialysis
or CAPD treatment or if it occurred before the treatment was
initiated (Table 3). These patients had renal failure but blood
sampling for AGE analysis was obtained before the initiation of
therapy. The AGE levels were elevated in these patients,
confirming that the AGE accumulation was not a consequence
of the treatment.
Molecular weight identification of AGE
One ml of a patient serum sample with high AGE concentra-
tion was dialyzed against 5 liters of saline overnight using a
dialysis membrane with a cutoff level of 12,000 Da. Analysis of
the AGE levels in the serum, after dialysis, showed an 80%
decrease, suggesting that AGE was effectively dialyzed. Similar
results were obtained when the sample was ultrafiltered using
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Amicon filters and centrifugation. To further identify the mo-
lecular weight of AGE, one serum sample was chromato-
graphed through a Bio-Sil SEC-250 column, 600 mm x 7.5 mm
(Bio-Rad Laboratories, Richmond, California, USA) using a
mobile phase of 0.1 mol/liter Na2SO4-0. 1 moL/liter NaH2PO4,
pH 6.80, at a flow rate of 0.5 mllmin. After injecting 1 ml
sample, 0.5 ml fractions were collected and analyzed for AGEs.
The column was calibrated with a molecular weight standard
solution from BioRad. The results are shown in Figure 6.
Clearly, AGEs elute at a peak corresponding to a molecular
weight of 1500 to 2000 daltons.
Discussion
Advanced glycosylation end-products are candidate pathoge-
netic factors of the long-term complications of diabetes. Exten-
sive clinical studies on AGEs, especially with assessment of the
Fig. 4. Correlations of AGE levels with
glucose, creatinine, age and sex. Left row (A)
represents the group of diabetic patients.
Middle row (B) are CAPD patients and right
row (C) hemodialysis patients. Statistically
significant correlations were observed only
with the creatinine levels. The correlation
coefficients r were 0.38 for A, 0.55 for B and
0.66 for C. M = male; F = female.
serum levels, are lacking partially because their measurement is
difficult and commercial assays are not available. This paper
describes an immunological assay for AGEs in serum, based on
a rabbit antibody that was raised with AGE-RNase as immuno-
gen, as described by Makita et al [9]. AGE formation was
followed by fluorometric procedures. Our competitive assay
utilizes a solid-phase AGE-BSA complex and a detection meth-
odology based on time-resolved fluorometry with terbium che-
lates as labels [10—12]. The assay was found to be precise,
accurate and easy to perform. No interference by simple sugars
or heparin was observed, in accordance with reports by three
other groups [7—9] which suggest that anti-AGE antibodies,
raised following the procedures described, react with an epitope
specific and common to all AGEs. This epitope is not present in
early glycosylated products or synthetic model AGE molecules
[91.
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Patient group
Fig. 5. Pre- and post-hemodialysis levels ofAGE (A) and creatinine (B)
in patients with renal failure: 1, 3, 5, pre-dialysis; 2, 4, 6, post-dialysis.
Patient groups were: non-diabetics (1,2; N = 6); NIDDM (3,4; N = 4)
and IDDM (5, 6; N = 1). The pre- and post-dialysis values were
compared by the t-test; the value of P in each case was: P = 0.001 for
AGE and <0.001 for creatinine (non-diabetics); P 0.036 for AGE and
0.001 for creatinine (NIDDM). No statistical comparison was done in
the patient with IDDM.
Fraction
70
Fig. 6. High performance liquid chromatography of a patient serum
sample with high AGE concentration. The position of the molecular
weight standards is shown by A (660 KDa), B (158 KDa), C (44 KDa),
D (17 KDa) and E (1.4 KDa). AGEs elute at a molecular weight of
approximately 1.5 to 2.0 KDa.
hemodialysis. No association was found between AGE levels
and sex, age or serum glucose levels. Other studies have shown
that AGEs pre-exist in patients with renal failure and are not the
consequence of the therapy.
The molecular weight of the circulating AGEs is around 1500
to 2000 Da as found by high performance liquid chromato-
graphic studies. Currently, it is believed that serum AGEs are
peptides in nature but this has not yet been confirmed, nor is
their precise structure known. We are currently examining if
the measurement of AGEs in serum by the immunological assay
described has clinical significance in predicting the long-term
complications of diabetic and non-diabetic nephropathy.
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